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Abstract 
Creating global alliances to fight disease and build infrastructure in developing and middle income 
countries has become a popular topic in the last several years. The global burden of disease and 
disparities in the level of health and healthcare make it difficult for any one group or funding source to 
make significant improvements in these areas, and in many areas of the world, the infrastructure simply 
does not exist. Global alliances have been instrumental in helping to build this infrastructure and research 
capacity, thereby reducing the impact of IDV/ AIDS, TB, malaria, and many other diseases. The ultimate 
goal of building sustainable capacity and infrastructure is to facilitate the transfer of knowledge gained 
through research into clinical practice and policy but it is a complex, resource-intensive process with 
many challenges. In 2005, the threat of an influenza pandemic led the National Institutes of Health and 
the Wellcome Trust to form the Southeast Asia Influenza Clinical Trial Network, supported by Oxford 
University and Family Health International. Although much progress has been made in a short time, 
challenges persist and the long term benefits have yet to be established. 
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Introduction 
Creating global alliances to build infrastructure and fight disease in developing and middle 
income countries1 has become a relatively common endeavor in the last ten to twenty years. A 
growing awareness of the shared burden of disease and the consequences of disparities in health 
and healthcare for global citizens has cast increased attention on the need for synergistic 
alliances that combine the strength, resources, and expertise of different sectors to help alleviate 
this unequal distribution (Widdus, 2001). As noted recently in Epidemiology, "Networks, by 
virtue of their greater scope, resources, population size, and opportunities for interdisciplinary 
collaboration, can address complex scientific questions that a single team alone cannot" 
(Seminara et al., 2007). Global networks have been formed and used successfully in the field of 
genome sequencing (Camargo & Simpson, 2003) and to reduce the impact of diseases such as 
HIV/AIDS, tuberculosis, malaria, polio, and river blindness by intervening at multiple points: 
community and household level, health-service delivery level, and at the policy and strategic 
management level (Bill and Melinda Gates Foundation, 2002; Travis et al., 2004). By working 
on health problems at multiple levels, the complex interplay of factors affecting population 
health can be addressed (Travis, et al., 2004). 
The broader picture encompassing this is the need to develop sustainable research capacity 
in developing and middle income countries. There is a growing recognition that a strong link 
exists between health and development (Dsselmuiden & Matlin, 2006; Lansang & Dennis, 2004; 
Pang, Sadana, Hanney, Bhutta, Hyder, & Simon, 2003). Investing in human, physical, and 
1 The World Bank defines low income countries as those with a yearly per capita income of :S $875 USD; 
middle income countries are defined as those with a yearly per capita income between $1.025-$6,055 USD. 
(htto://web. worldbank.org; accessed 3/27/2007) 
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intellectual capital works to improve global health by stimulating economic development and 
improving the health of both individuals and populations (Distlerath & Macdonald, 2004; Pang 
eta!.). In essence, a positive feedback loop is created. Improved population health increases the 
capacity for economic development; in turn, economic development spurs better health 
outcomes. 
This paper will examine how networks can be used to build sustainable research capacity, 
some of the challenges of building them and some of the practicalities involved. Finally, this 
paper will discuss the formation and considerations of the Southeast Asia Influenza Clinical 
Research Network, a two-year old alliance, as it seeks to develop centers of clinical research 
excellence that can respond to influenza and other emerging infectious diseases in participating 
countries. 
Building Sustainable Research Capacity 
By strengthening health research capacity, global networks have been cited as one way to 
alleviate a funding disparity termed the "10/90 gap." The "10/90 gap" refers to the fact that only 
5-10% of all global research funding is targeted towards health problems that are responsible for 
90% of the world's health problems (Global Forum for Health Research, 2006; Ranis, 2004; 
McCoy, Sanders, Baum, Narayan, & Legge, 2004). In order to close the "10/90 gap," it is 
important to develop research capacity that is sustainable over the long term and research 
systems that can "define and prioritize problems systematically, develop and scientifically 
evaluate appropriate solutions, and share and apply the knowledge generated" (Lansang & 
Dennis, 2004, p. 765). Both long and short-term strategies must be formulated and directed at 
individual, institutional, and national levels in order to create sustainable systems of health 
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research. To promote sustainability, research must focus on the social, economic, and political 
determinants of health, especially as they relate to clinical and biological research. Lastly, there 
must be a mechanism for the successful transfer of knowledge from research into policy and 
practice (McCoy et al., 2004). 
The ultimate goal is to create a health research system that encompasses all types of 
research "including biomedical, clinical, epidemiological, health systems and policies research, 
socioeconomic and behavioural research .. .it also includes research not usually considered to be 
health related-for example, engineering studies to improve car or road safety or economic 
research leading to policy changes that affect poverty" (Pang eta!., 2003, p. 816). Recognition 
that capacity building within a country or region takes place within a larger environment of 
socioeconomic and political circumstances is crucial. For efforts to be sustainable, they must 
take into account the local politics, economics, and institutions; to be effective, they must be 
"country-owned" rather than "donor-driven" (Dayrit, Morin, & Matlin, 2006). The Global 
Forum for Health Research recommends that developing countries devote 2% of their national 
health expenditures to build research capacity and that donor organizations allocate 5% of their 
budgets to this function to help ensure sustainability over the long term (Usselmuiden & Matlin, 
2006). 
Private, for-profit, non-governmental/non-profit organizations, and foundations have 
combined in various ways to create alliances, recognizing that the health problems in developing 
and middle income countries are too complex to be remedied by the actions of any single person, 
organization, or sector. These partnerships "involve a diversity of arrangements, varying with 
regard to participants, legal status, governance, management, policy-setting prerogatives, 
participants, contributions, and operational roles" (Widdus, 2001, p. 717). Although some such 
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alliances have been primarily focused on research and development, the majority have been 
partnerships of donation and distribution whereby medications for disease control are distributed 
among those in need while efforts are made to see that the product is used effectively. Although 
there are welcome short term benefits to this type of arrangement, in the absence of other sector 
services the drugs themselves do not usually address the health problems of highest priority. To 
be truly successful and sustainable over the long term, partnerships must strengthen healthcare 
service infrastructure, delivery, and outcomes while addressing the issues that are pertinent to the 
local area served (Widdus, 2001). 
To this end, the early stages of network development may include logistical steps, such as 
helping scientists "gain access to education, training, funding, information, equipment and 
supplies" (Harris, 2004, p. 7). Although some middle income countries have advanced avenues 
for scientific development such as graduate, doctorate and post-graduate programs, low-income 
countries may not. In many low-income countries, research is not considered to be a priority or a 
"profession" and therefore is seen as an activity to be done "on the side" with many researchers 
holding multiple jobs in order to earn an adequate income or leaving their countries to pursue 
more lucrative opportunities. Funding that allows for researchers to be fully dedicated to 
research can help alleviate this problem. 
Equipment and Training Considerations 
Strengthening capacity and infrastructure in middle income and developing countries may 
require expenditures for equipment and facilities in order to conduct research. For example, 
laboratories may not have the equipment to perform certain tests, so the network may have to 
invest in facility renovation and then provide the equipment, associated systems, and reagents 
(Pang et a!. 2003). Once the new equipment is purchased and installed, the training of lab staff 
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on its operation can begin, but to encourage sustainability, this training should not be strictly 
process oriented (i.e., how to run the newly purchased lab equipment). Network collaborators 
should incorporate a broader based training. For example, teaching epidemiological surveillance 
methods alongside laboratory technique helps regional scientists understand local disease 
patterns and gives them an opportunity to provide input on the design of appropriate 
interventions. Laboratory staff can also be trained on international standards of laboratory 
practice, which, when incorporated over time, can improve the practices of local laboratories. 
By training research scientists on proposal development, grant-writing, and manuscript writing 
skills, additional steps are taken to foster sustainability (Harris, 2004). 
Other individuals new to research may require training as well. Initially, training should 
follow a careful needs assessment in order to be responsive to the requests of local staff, should 
encourage group participation, including examples and situations that are applicable to the local 
environment, and be as hands-on as is possible. Whenever feasible, local and regional experts 
should serve as instructors. As more individuals receive training and become proficient in the 
subject matter, they can become local and regional trainers. Training conducted by instructors 
who work under similar conditions and constraints as the trainees helps build trust and 
empowerment (Harris, 2004). 
Goal setting 
In developing and increasing capacity at the local and national levels, network 
collaborators should create short and long term goals. Short term goals may be task-oriented, 
such as purchasing equipment, up-fitting facilities, and hiring staff. A long-term goal of the 
network alliance, however, must be to engender an environment that is conducive to research and 
a career ladder that will entice and retain talented individuals. "This includes good research 
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management, availability of funding for research, opportunities to present and openly discuss 
research data, and ... rapid access to current research information" (Pang et al., 2003, p. 817). 
Additionally, the alliance should develop leadership and management competencies among local 
researchers. Skills that need to be advanced include "strategic planning; research priority setting; 
knowledge management; advocacy and demand creation; consensus building and negotiation; 
resource generation and allocation; partnership building across many stakeholders; 
communications, including virtual forms of networking; financial management; and systems 
perlormance assessment" (Lansang & Dennis, 2004, p. 767). Attempts should be made to have 
training sessions on a regular basis to ensure that new researchers and other team members are 
kept up to date on new and current research and practice. 
To reap the benefits of a collaborative effort, the network should have a well defined, 
compelling overall goal and scope (Bill and Melinda Gates Foundation, 2002). Seminara et al. 
state that "Elements deemed essential for launching a network are a strong scientific rationale, 
the agreement of all teams to work together and combine data on overarching research questions, 
and the ability to support initial communication, coordination, identification, and recruitment of 
partners" (Seminara et al., 2007, p. 2). Beyond this, managers and donors must have an 
understanding of what value is obtained from working within an alliance and what is needed to 
attain that value; determine an appropriate structure for the alliance; determine what metrics will 
be used to measure success, how milestones will be met, and contributions of other partners; and 
create models for governance that allow for effective and efficient decision-making while 
allowing for input from network members (Bill And Melinda Gates Foundation, 2002). 
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Benefits of Working Within an Alliance 
There are many benefits of working within an alliance, including: avoiding duplication of 
investments and effort; gaining economies of scale, sharing or reducing risks to allow new 
initiatives to take place that individual partners or donors might not have been able or willing to 
take on alone; sharing knowledge, resources, and best practices to improve effectiveness; and 
accelerating momentum and attracting funding by building a common "brand" that gains 
legitimacy and monetary support (Bill And Melinda Gates Foundation, 2002). Other valuable, 
but less tangible, benefits of collaboration include "new and better ways of thinking about health 
issues" (Lasker, Weiss, & Miller, 2001, p. 184). This can include creative thinking, 
comprehensive thinking, practical thinking, and transformative thinking. 
Creative thinking occurs when partners come together, more voices are heard, and 
differences are explored, which in tum welcomes new ideas and innovations. When working 
alone, individuals or organizations may only see one facet of a problem or issue. When working 
in collaborations, however, they may experience comprehensive thinking in that they can 
"construct a more holistic view-one that enhances the quality of solutions by identifying where 
multiple issues intersect and by promoting broader analyses of problems and opportunities" 
(Lasker et al., 2001, p. 184). Practical thinking is an outcome of collaboration because 
academics and health professionals come together with those who are most affected by a health 
problem, and therefore, there is the possibility of solutions that bridge science to local 
experience, culture, and capability. Finally, collaborating with partners who have different 
assumptions, expectations, and ways of working may bring about change in.the mindset of 
individuals and organizations involved in the process and allows for innovative thinking and 
ideas to be brought to the forefront (Lasker et al., 2001). 
Global Alliances 10 
Drawbacks ofWorking Within an Alliance 
For all the advantages of working within a collaborative network, there are costs and 
frustrations as well. First, development of a network is time consuming and resource intensive 
as relationships are established, goals are set, and work is initiated. Collaborations involve 
multiple groups that are each used to working in their own ways and within their own form of 
governance, and weaker partners within an alliance may not see an immediate return on their 
investment of time and resources. Diversity among partners and cultures can create conflict and 
tension if differing needs and assumptions are not addressed. Individuals may have to ignore or 
abandon other priorities and obligations, leading to conflict between network activities and other 
job-related responsibilities. Governance issues can lead to frustration, particularly in the areas of 
communication and decision making if partners do not have a defined communications plan and 
a voice in the decision making process. Partners within the alliance may not feel that their 
contributions are adequately recognized and appreciated (Bill And Melinda Gates Foundation, 
2002; Lasker, Weiss, & Miller, 2001). Working within the extra layers of bureaucracy and 
differing regulatory requirements in member countries can also create delays as documents make 
their way back and forth through multiple agencies. 
Although it is crucial to have organizational partners feel they are all working on the 
same team, differences in language, culture, and even working across multiple time zones can 
make team-building difficult. In the absence of daily face to face contact, conflicts can intensify 
as they are not easily managed from afar. Successful collaboration hinges upon creating an 
atmosphere of trust, and trust can be the one of the most important, but most difficult, areas to 
achieve. Creating clear goals and expectations and conveying them to all parties, allowing for 
face to face meetings when possible, providing frequent feedback, giving credit for tasks that 
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have been accomplished, fostering cultural understanding, and making the work visible and 
transparent are steps that can be taken to build trust (Ross, 2006). 
When alliances are able to implement sustainable programs that provide important 
research, it may afford a country or region a greater opportunity to address broader determinants 
of health by bridging scientific knowledge to local culture. With this information, local 
researchers and policy-makers can better analyze the burden of disease in a particular area, set 
priorities, hasten the implementation of research findings to confront health problems, and create 
new tools to fight the disparities and inequities of current policy (Sitthi-amom & Somrongthong, 
2000). As stated by Pang, et a!., "Knowledge produced by health research, if disseminated 
widely, is a global public good. Knowledge contributes to the policies, activities, and 
performance of health systems" (Pang, 2003). 
Background on infectious diseases 
Emerging infections, those that appear for the first time or those that were known to exist 
but that increase in incidence or geographic range, have been documented for thousands of years. 
Biblical plagues, bubonic plague, smallpox and measles are just a few examples of emerging 
infections that decimated large populations. Today, infectious diseases-- particularly those found 
in tropical and subtropical regions--kill upwards of 15 million people a year, and over 90% of 
those deaths are in developing countries. Infants and children are particularly hard-hit with over 
3 million deaths annually from malarial and diarrheal diseases. Many of these infections are 
thought to result from microbial evolution, development of microbial resistance, zoonotic 
encounters, and environmental encroachment. Cyclical re-emergence of disease may also be 
climate-related, as in the re-appearance of cholera and malaria (Morens, Folkers, & Fauci, 2004; 
World Health Organization, 2004). 
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Influenza 
Documented influenza pandemics occurred in 1888, 1918, 1957, and 1968. The pandemic 
of 1918-1919 killed an estimated 50 million people worldwide and led to major social and 
economic disruption. Although the timing of the next pandemic cannot be predicted, scientists 
feel that one will occur at some point in the future (United States Department Of Health And 
Human Services, 2007) As described by Morens, Folkers, & Fauci, 
Although much remains speculative about how influenza viruses emerge and spread, it 
seems clear that the process is driven by prolific and complex viral evolution (genetic 
reassortment and mutational 'drift'), interspecies mixing and adaptation, and ecological 
factors that bring humans into contact with animals and each other. By whatever means 
new influenza virus pandemic strains emerge, they eventually reach a critical threshold of 
human transmission beyond which epidemic and pandemic spread follows 
mathematically predictable patterns (Morens et al., 2004, p. 247). 
In 1997, the emergence of avian influenza (H5N1) infections in humans fueled fears across 
the globe of a new pandemic. Since then, the H5N1 strain has been found in wild and domestic 
birds and poultry throughout Asia, Europe, Africa and the United Kingdom (World Health 
Organization, 2007). Transmission to humans has occurred through direct and indirect contact 
with infected birds and there have been over 288 confirmed cases of H5N1 in humans since 
2003. The current mortality rate is about 60% among those who have been infected (World 
Health Organization, 2007). Avian influenza is difficult to transmit from human to human, but 
there have been at least two suspected cases of human to human transfer and multiple outbreaks 
in family clusters in Indonesia and Vietnam. The H5N1 virus is more pathogenic than other 
influenza strains and, according to a statement by Anthony Fauci, MD, the Director of the 
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National Institute of Allergy and Infectious Diseases (NIAID) at the National Institutes of 
Health, H5N1 
is evolving in ways that increasingly favor the start of a pandemic, including becoming 
more stable in the environment ... Given the poor condition of public health systems in 
many underdeveloped regions and the speed of modern air travel, the consequences of such 
an event, should it result in an influenza pandemic, would be severe (United States 
Department Of Health And Human Services, 2005, p. 2). 
NIAID support of influenza research 
NIAID has been supporting influenza research for many years, and has been involved with 
many projects aimed at increasing understanding of how influenza viruses replicate, interact with 
their host organisms, stimulate immune responses, and evolve into new strains. Fueled by 
growing fears of a pandemic, funding for influenza research by NIAID has grown rapidly since 
2001. In fiscal year 2001,$20.6 million was spent on influenza research; by fiscal year 2005, the 
estimated amount was $119 million. Since 2004, NIAID has been involved with an influenza 
genome sequencing project with the Centers for Disease Control and Prevention (CDC) and 
several other organizations to determine the complete genetic sequences of thousands of 
influenza viruses and to provide this data to scientists. They are also involved with a 
surveillance program based in Hong Kong to detect the emergence of influenza viruses in 
animals that have pandemic potential. Surveillance activities also occur in Vietnam, Thailand, 
and Indonesia as a part of this program (United States Department of Health And Human 
Services, 2005). 
Part of NIAID's activities since 2001 have included vaccine development and studying the 
use of four different antiviral medications for prophylaxis and treatment of influenza. Research 
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has shown that H5Nl strains currently being isolated in Southeast Asia and Africa are resistant 
to two of the antivirals, rimantadine and amantadine. However, two other antivirals, oseltamivir 
and zanamavir, both of which are neuroaminidase inhibitors, are effective against most of the 
isolates found in these regions. In response to these findings, the NIH, and NIAID particularly, 
have 
collaborated with the World Health Organization (WHO), the Wellcome Trust, and other 
institutions in Indonesia, Thailand, Vietnam, and the United Kingdom to develop the 
South East Asia (SEA) Influenza Clinical Trial Network (SEA Network), which is 
developing in-country research capacity in a region directly infected by the H5Nl 
influenza outbreak and conducting studies of antivirals in people affected with the H5Nl 
virus (United States Department Of Health And Human Services, 2007). 
Formation of the Southeast Asia (SEA) Influenza Clinical Trial Network 
Discussions regarding the concept of the SEA Network began as a dialogue between 
NIAID and the WHO in 2004 about what efforts might be useful in helping researchers in 
Southeast Asia learn more about the influenza viruses being isolated there. Representatives from 
the WHO identified that there was a gap in clinical research capabilities in the region. Due to the 
pressing nature of the problem and limited resources, researchers in SEA felt that a network 
approach would be the best way to study the pandemic threat of H5Nl. With input from these 
researchers, NIAID and the WHO developed a short list of what was needed and wanted by 
potential partner participants: to support clinical research that works for countries where avian 
and human influenza is occurring, to build infrastructure and research capacity, and to share 
information. Interest among institutions within the countries affected by HSN 1 grew from there. 
After these discussions, NIAID approached Oxford University and the Wellcome Trust and the 
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SEA Network was formed in 2005 (Elizabeth Higgs, MD, NIAD, personal communication 
February 21, 2007). The network has now grown to include 20 partners in six countries: 
Indonesia: 
• Eijkman Institute, Jakarta 
• Persahabatan Hospital, Jakarta 
• Sulianti Saroso Hospital, Jakarta 
• National Institute for Health Research and Development, Jakarta 
• U.S. Naval Medical Research Unit No.2 (NAMRU 2), Jakarta 
Thailand: 
• Queen Sirikit National Institute of Child Health, Bangkok 
• Siriraj Hospital, Mahidol University, Bangkok 
• Chest Disease Institute, N onthaburi 
• Bamrasnaradura Infectious Disease Hospital, Nonthaburi 
• Faculty of Tropical Medicine, Mahidol University, Bangkok 
Vietnam: 
• National Institute for Infectious and Tropical Diseases, Hanoi 
• National Hospital of Pediatrics, Hanoi 
• Hospital for Tropical Diseases, Ho Chi Minh City 
• Children's Hospital# 1, Ho Chi Minh City 
• Children's Hospital# 2, Ho Chi Minh City 
United Kingdom/Europe: 
• Oxford University, UK 
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• Wellcome Trust, UK 
• World Health Organization, Geneva, Switzerland 
United States: 
• National Institute of Allergy and Infectious Diseases (NIAID), Bethesda, MD 
• Center for International Research and Support (CIRAS), a group within Family Health 
International, Durham, NC 
Funding for the SEA Network comes primarily through NIAID and the Wellcome Trust 
(Southeast Asia Influenza Clinical Research Network [SEA ICRN], 2006). 
Network structure. 
The structure of the Network currently includes a Network Steering Committee (NSC), 
Trials Operation Committee (TOC), Network Coordination Center, Center for International 
Research and Support (CIRAS), and an independent Data Safety and Monitoring Board 
(DSMB). A Network organizational chart and a chart depicting the protocol development 
process are attached as Appendix A. The Network Steering Committee provides overall 
leadership to the Network, including the Network's mission and objectives; membership; 
prioritization and timing of clinical trials; oversight of the TOC and DSMB; policies for 
publication and presentation; administrative issues for the Network; external relations including 
interactions with national and/or international media; and expansion of Network-related training 
capacities. Membership on the NSC is comprised of one voting representative from each of the 
participating country and international institutional partners. Members serve for 2-4 year terms 
and they may serve no more than twice, although their terms do not have to be consecutive. 
Each country is responsible for choosing its own representative. Each protocol has its own 
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Protocol Committee with representation from several sub-committees that deal with specific 
areas essential to the conduct of clinical trials including Data Management, Clinical Operations, 
Pharmacy, Regulatory, and Site Management. Members on these committees represent the 
various partner institutions. 
NIAID has contracted with SAIC-Frederick, an operations and technical support contractor 
for the Department of Health and Human Services based in Frederick, MD to hold sub-contracts 
with CIRAS, a group within Family Health International (FHI), a public health research 
organization based in Durham, NC and Pharmaceutical Product Development, Inc. (PPD), a 
contract research organization based in Wilmington, NC. CIRAS provides administrative 
support, technical and operational training to the sites, support to the DSMB, and helps with the 
activities of the NSC, TOC, and other Network committees. (SEA ICRN, 2006) CIRAS is 
officially based in the Durham, NC offices of FHI, but there are CIRAS team members, called 
Clinical Trial Support Specialists (CTSS), in FHI offices in each of the member countries of the 
Network. The role of the CTSS's, who are native language speakers, is to work closely with the 
study sites, providing technical assistance and guidance to them, as well as on-site study 
management support if needed. PPD has been hired to fulfill contractual duties of monitoring 
the conduct of the clinical trials done by the network; however, due to the nature of their contract 
with SAIC, their role in the study is not discussed in this paper. 
Objectives of the Network 
As stated on the Network website, the Network objectives are: 
(1) build a multilateral, collaborative network based on shared principles of respect and 
commitment to improve patient management through quality clinical research; (2) 
conduct protocol-based, multi-institutional studies in human influenza in accord with 
Global Alliances 18 
international standards; (3) enhancing international capacities for the conduct of clinical 
research; (4) promptly disseminating information and sharing samples based on approval 
of the relevant national ministries of health and other relevant national authorities with 
the aim of improving human health. Protocols may be aimed at the diagnosis, 
pathogenesis, treatment, and prevention of human influenza, with the goal of producing 
data and evidence that will be used to help guide health policy and clinical practice in SE 
Asia (SEA ICRN, 2006). 
One of the missions of the Network is to enhance the clinical research capacity of 
individuals and institutions within the Network. This will be accomplished through scientific 
training, and instruction in leadership, management, conduct, administration, and oversight of 
studies. Eventually, this will include "training of staff in conducting studies according to 
international guidelines, developing laboratory and diagnostic expertise, enhancing institutional 
support structures for conducting and overseeing studies, and fostering education ... A long-term 
goal. . .is to develop centers of clinical research excellence that could respond to other emerging 
infectious diseases in participating countries" (SEA ICRN, 2006). 
Training efforts 
Training member institutions and their study staff are integral to the success of the 
Network and theses activities have been ongoing since early 2006. In March 2006, a Network 
Kickoff Meeting was held in Hanoi, Vietnam to bring together representatives from the 
partnering institutions for training. Sessions were held to acquaint participants with the Network 
and other member institutions and to provide instruction on influenza, Good Clinical Practice, 
protocol training on the first clinical trial to be conducted in the Network, regulatory topics, and 
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data management, among others. In August and September 2006, 3-day sessions were held in 
each of the member countries (Vietnam, Thailand, and Indonesia) on Good Clinical Practice and 
Research Ethics. Research Ethics training is required for anyone working on projects funded by 
NIH. 
Protocol Specific Training 
Training of pharmacists and data managers. 
The first clinical trial to be conducted within the network is a standard-versus high-dose 
trial of oseltamivir in patients:,. 1 year old with severe and/or avian influenza. Each clinical site 
that has been chosen has many ancillary staff that will be working on the· study; many are new to 
research so they have required more intensive training than is normally done in U.S. clinical 
research centers. In July, data managers from each member country traveled to North Carolina 
for a week-long data management training session. A five-day pharmacy training took place in 
August 2006 in Bangkok, Thailand for the lead pharmacists in each country. 
Training of trainers (TOT). 
In September, Clinical Trial Support Staff (CTSS) from CIRAS Asia were brought to 
Bangkok for a one-week "Training of Trainers" session. Staff from CIRAS North Carolina, 
NIAID, and Oxford University led training sessions on various aspects of the operational 
management of the first clinical trial to be conducted, including protocol training, regulatory 
aspects of clinical trials, and methods of adult learning. As much as possible, these training 
sessions were participatory in order to create a comfort level among the CTSS 's because the 
CTSS's then returned to their respective member countries to lead week-long protocol-specific 
training there. 
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Study-initiation training. 
Study staff from all participating clinical sites were brought to one city in each country for 
training on the topics that had been covered at the TOT in Bangkok. Because English is not the 
primary language of most of the trainees, trainings in the member countries were conducted in 
local language. Staff from CIRAS North Carolina and NIAID went with the CTSS's and 
received simultaneous English back-translation of the sessions to ensure that the CTSS's were 
sharing correct information. While site staff training was ongoing, other staff from CIRAS 
North Carolina, CIRAS Asia, NIAID, and Oxford University conducted abbreviated training 
sessions for study investigators and sub-investigators in English. 
Site-specific training. 
After the country-level trainings were completed, the CTSS's traveled to each of the 
clinical sites within their country to conduct two-day on-site training on how to operationalize 
the study at their respective institutions. During this training, site staff worked through seven 
influenza clinical case studies developed by CIRAS NC that were designed to make them think 
through study-related processes and then determine how and where study-related procedures 
would be carried out at their site. In addition, they worked on drafting site-specific standard 
operating procedures to be used during the study. 
Additional trainings. 
In November 2006, data managers from CIRAS-NC traveled to Asia to do more in-depth 
data management training with sites and regional data management centers. In early 2007, staff 
from Oxford University's Vietnam laboratories conducted training at each site on computer 
software that will be used to track virology and pharmacokinetic specimens that will be obtained 
as part of the study. Due to regulatory and logistical delays in starting up the initial study, 
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CIRAS NC and the CTSS' s led in-country refresher training sessions on various aspects of the 
study in January-April, 2007. As a result of all of these training sessions, over 250 study staff 
have received instruction (Southeast Asia Influenza Clinical Research Network, 2006). The first 
participant is expected to be enrolled in this trial in early-mid April 2007. 
Yearly Network meetings. 
Yearly Network meetings are planned to bring investigators and study staff together for 
refresher training as well as protocol updates and training in new content areas. In order to 
perpetuate a sustainable research network, it is felt that this training must be held regularly to 
keep current researchers up to date on best practices and standards and to equip those moving 
into the field of research. Training sessions will be geared towards not only physicians, but also 
nurses, research managers, laboratory technicians, data managers, pharmacists, and other study 
support staff. The next yearly Network meeting is planned for May 16-18, 2007. A proposed 
agenda for this meeting is attached in Appendix 2. Although much of the focus will be on 
influenza and the Network studies, other training sessions will cover broader research topics such 
as considerations for clinical trial design, mathematical modeling, and protocol development. 
The Network also plans to identify and support junior researchers who would be "sponsored" 
and mentored by a senior member of the Network. 
The extensive trainings that have been done to launch the first study may or may not be 
adapted and utilized with other studies done by the Network. However, the Network is clear in 
its Mission Statement that training in research is crucial to guaranteeing its sustainability. The 
benefit of research training lies in building the capacity of individuals and institutions "to 
conduct clinical research that meets international academic standards, regulatory requirements 
and ensure patient safety and the highest standards of clinical care" (SEA ICRN Training Plan, 
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draft 1, 5 Feb 2007). This in turn should help institutions in the future as they work individually 
or with other partners to reduce the disease burden in their respective countries by transferring 
the knowledge learned through research to clinical practice and by informing government 
policies. 
Logistical Challenges to the Development of the SEA Network 
Communication 
Although much has been accomplished in the last two years to establish the SEA Network, 
there have been logistical challenges to initiating the first planned study. In effect, the Network 
has functioned much like a virtual team, since partners are spread across the globe. A relatively 
simple task, such as planning a teleconference becomes more difficult because there are two or 
three different time zones to consider. International teleconferences are set up with a toll-free 
dial-in number; participants from Indonesia and Thailand can call in,. but participants from 
Vietnam cannot dial a 1-800 service and therefore have to be dialed in by an international 
operator. Connectivity and voice quality are often poor. The eleven or twelve hour time 
difference between the US and Asia means that office hours do not overlap leading to lags in 
communication. 
Language differences also must be considered. English is not the local language in any of 
the countries where the Network is conducting its clinical trials, and proficiency in speaking and 
understanding it varies widely among the study staff in each country. This has necessitated the 
translation of study manuals and informed consents into local languages. Having the materials 
translated and then back translated into English in order to verify the accuracy of the translation 
adds another layer of time and complexity into the process of study start-up. 
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Cultural Differences 
Cultural differences and holidays in the member countries have led to the re-working of 
work and training schedules. In Vietnam and Indonesia, it is considered rude if former students 
are put into positions of teaching their former professors, so some of the CIRAS-Asia staff who 
had trained under the study investigators could not lead training sessions in which their former 
teachers were going to be the trainees. Indonesia is a predominantly Muslim country, so 
schedules for study initiation training sessions in October 2006 had to be rearranged due to 
Ramadan. During the yearly celebration of Tet in Vietnam, offices are closed for up to two 
weeks and work virtually comes to a halt. 
Trust Building 
Building trust among participating institutions has been a slow process. A lack of clear 
contracts, communications plans, and clear communication regarding which group is charged 
with completing specific tasks, and inconsistent decision making has made the development of 
trust more difficult, although some advances have been made in the last several months. 
Network partners have become more comfortable with each other and have developed more 
harmonious working relationships as individuals from partnering institutions have had more 
chance to interact during trainings and regional meetings. 
Communications within the Network 
Teleconferences 
Teleconferences for the committees and teams within the Network have been an essential 
part of the communications process and have helped foster the development of trust between 
Network members. Most of the Network committees and subcommittees have set up monthly 
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calls and CIRAS, Oxford, and NIAID staff conduct weekly project tracker calls to monitor the 
progress of study and Network activities. CIRAS NC and CIRAS Asia also have weekly 
teleconferences to get updates from the CTSS assigned to each country; this information is 
shared with Oxford and NIAID during the weekly tracker calls. These teleconferences are also 
used to discuss internal issues and create action items for the NC and Asia teams to address. 
Minutes drafted from the committee and tracker c;alls are posted on an internet-based portal, 
Sharepoint, which is maintained by CIRAS, for review and comment prior to finalization. These 
minutes can be accessed and edited by anyone who has been granted privileges to use the portal. 
Sharepoint 
The internet based portal, Sharepoint, is a restricted-access repository for internal study 
documents and can be accessed by CIRAS NC, CIRAS Asia, certain staff at NIAID, and their 
sub-contracted company SAIC-Frederick. There have been problems with slow internet access 
due to low bandwidth, particularly in Indonesia, that have made it difficult for the CTSS's there 
to log on and use Sharepoint. The application is also not entirely intuitive and training people to 
use it correctly has been challenging. 
SEA Network Website 
As already noted, the SEA Network has developed a web site which is also maintained by 
CIRAS. Network information, information about partnering organizations and institutions, 
protocols, protocol specific documents such as training manuals and training presentations, and 
other resources are posted on the site. This website has been an invaluable tool for spreading 
information about the Network, and provides a central source for study sites that have internet 
access to retrieve protocol related materials. 
Logistical Challenges of Operationalizing a Study 
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Equipment and Facilities 
There have been logistical issues that have required attention to bring the individual clinical sites 
up to generally acceptable standards for conducting international clinical trials. These are 
conditions that are generally taken for granted in the United States, but are not always standard 
in developing countries and which add delays to getting a study started. At some of the clinical 
sites, air conditioning is not available in all areas of the hospital or is only available during 
certain hours of the day and not on weekends. The study drug for the initial trial, oseltarnivir, 
must be stored below 25° Celcius, so air conditioning had to be installed in some of the 
pharmacies. Locked storage cabinets for investigational products are not widely available, so 
these had to be ordered and installed. Uninterruptable power sources are not available at all 
centers, so back-up generators for power supply have been purchased for sites that needed them. 
Laboratory equipment has been purchased so that the local labs will have the equipment that they 
need to conduct the testing required by the protocol(s). During laboratory inspections conducted 
to determine which hospitals would be clinical sites for the first trial, it was not uncommon to 
find reagents several years out of date, so the Network has provided each site with all the kits, 
reagents, and probes that will be needed for the analysis of protocol-required specimens. Some 
of the virology and genetic phenotyping studies to be done as part of the initial protocol can only 
be done at one of the labs in Vietnam and there have been multiple issues around shipping 
hazardous specimens across international borders. Study offices and one of the data 
management centers required renovations to provide internet access which is required for the 
study. 
Regulatory Approval Process 
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The regulatory approval process has posed additional challenges to study start-up. 
Protocols generated by the NIH, such as the protocol for the initial study, have to go through an 
approval process by the NIH Institutional Review Board, as required by the Food and Drug 
Administration. Once that step is completed, the protocol and other documents are released to 
the individual countries, where the documents are translated into local language and then back 
translated into English for verification of accuracy. Then the approval process starts over with 
each country's Ministry of Health (MOH) and local Ethics Committees (EC). If the country 
MOH or local EC requests any changes to the protocol or informed consent or if there is a 
protocol amendment, the whole process has to be repeated. 
What Does the Success of the Network Look Like? 
The Network has only been in existence for about two years and although there have been 
significant accomplishments, the process has not moved as smoothly as was initially hoped. A 
single-center pharmacokinetic study is currently underway in Thailand, and the study that was 
supposed to be the first study for the Network has not yet enrolled its first participant. Several 
more clinical studies are in the proposal stage or have been approved for development by the 
Network Steering Committee, but have not advanced beyond that point. Long-term markers of 
success may be more difficult to define and assess in a way that is evidence-based. According to 
Elizabeth Higgs of NIAID, success will be a self-sustaining Network that goes on when the 
funding from the National Institutes of Health ends. Researchers within the Network will be 
publishing their data in peer-reviewed journals and will be competing successfully for 
international grants. Once the Network is fully established and running smoothly, it is hoped 
that the research done by network participants will be used to inform health policy and clinical 
practice in the member countries. Although the presence of avian influenza in SE Asia was the 
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impetus for the formation of the Network, Dr. Higgs would like to see the scope of the Network 
broaden as new diseases emerge. Finally, she would like to see trust and relationships deepened 
and richened by years of collaboration (Elizabeth Higgs, MD, NIAD, personal communication 
February 21, 2007). 
Conclusion 
Developing a research network is a time-consuming process with many challenges, some of 
which are anticipated and some are not. Some are easily dealt with, but others are more difficult. 
For the SEA Network, the intentions for success are there as are the building blocks, but the 
political environments in which the Network functions do not guarantee achievement. Short 
term solutions will be easier to bring about than long-term ones. Improvements in healthcare and 
decreased mortality from influenza may be easier to accomplish than creating deep-seated 
change and transferring research into practice and policy. Travis et a!. makes the argument that 
focusing on a specific disease is short-sighted because concentrating resources in specific 
programs can lead to under-resourcing of other areas. This results in only limited gains because 
efforts do not address issues such as an inadequate health workforce, limited drug supply, 
financing, and information systems (Travis, eta!., 2004). If the results of research generated by 
the Network are to be used to improve the health of people in Southeast Asia, support from the 
highest levels of government in the member countries is critical. Greater investment in research 
can lead to better health outcomes but the member countries have to begin to take more and more 
of this responsibility on themselves and rely less on international funders. At this point in time, 
it is too early to assess whether the SEA Influenza Clinical Trial Network will be successful in 
helping its institution and country members achieve these goals. 
Global Alliances 28 
References 
Bill And Melinda Gates Foundation (2002). Developing successful global health alliances. 
Washington, DC: U.S. Government Printing Office. 
Camargo, A. A., & Simpson, A. J.G. (2003). Collaborative research networks work. The Journal 
of Clinical Investigation, 112(4), 468-471. 
Dayrit, M., Morin, 0., & Matlin, S. A. (2006, September). Global gaps in research, capacity 
building, and health resources. Presented during a plenary session at the meeting of the 
Geneva Forum on Health--Towards Global Access to Health. Retrieved January 19,2007 
from http://www.genevahealthforum.com/reports/40 
Distlerath, L. M., & Macdonald, G. (2004). The African comprehensive HlV/AIDS partnerships-
-a new role for multinational corporations in global health policy. Yale Journal of Health 
Policy, Law, and Ethics, 1-8. Retrieved February 7, 2007, from UNC Health Sciences 
Library Web Site: http://web.lexis-nexis.com.libproxy.lib.unc.edu/univers/printdoc 
Global Forum For Health Research. (2006). Global Forum for Health Research: Helping 
Correct the 10190 Gap. Retrieved February 21, 2007, from http://globalforumhealth.org 
Harris, E. (2004). Building scientific capacity in developing countries. European Molecular 
Biology Organization, 5(1), 7-11. 
Dsselmuiden, C., & Matlin, S. (2006). Why Health Research? Retrieved February 19, 2007 from 
http://www.globalforumhealth.org/filesupld!Why%20Health%20Research/Why%20Healt 
h%20Research%20Research%20-%20vol. %20 1.pdf 
Global Alliances 29 
Lansang, M. A., & Dennis, R. (2004). Building capacity in health research in the developing 
world. Bulletin of the World Health Organization, 82(10), 764-770. 
Lasker, R. D., Weiss, E. A., & Miller, R. (2001). Partnership synergy: a practical framework for 
studying and strengthening the collaborative advantage. The Milbank Quarterly, 79, 179-
205. 
McCoy, D., Sanders, D., Baum, F., Narayan, T., & Legge, D. (2004). Pushing the international 
health research agenda towards equity and effectiveness. The Lancet, 364, 1630-1631. 
Morens, D. M., Folkers, G. K., & Fauci, A. S. (2004). The challenge of emerging andre-
emerging infectious diseases. Nature, 430, 242-249. 
Pang, T., Sadana, R., Hanney, S., Bhutta, Z. A., Hyder, A. A., & Simon, J. (2003). Knowledge 
for better health--a conceptual framework and foundation for health research systems. 
Bulletin of the World Health Organization, 81(11), 815-820. 
Ross, J. (2006). Trust makes the Team Go 'Round. Harvard Management Update, 3-6. 
Seminara, D., Khoury, M. J., O'Brien, T R., Manolio, T., Gwinn, M. L., Little, J., eta!. (2007). 
The emergence of networks in human genome epidemiology: challenges and 
opportunities. Epidemiology, 18(1), 1-8. 
Sitthi-amom, C., & Somrongthong, R. (2000). Strengthening health research capacity in 
developing countries: a critical element for achieving health equity. BMJ, 321, 813-815. 
Southeast Asia Influenza Clinical Research Network. (2006). Mission Statement. Retrieved 
February 21, 2007, from http://www.seaclinicalresearch.org 
Travis, P., Bennett, S., Haines, A., Pang, T. Bhutta, Z. Hyder, A. A., eta!. (2004). Overcoming 
health-systems constraints to achieve the Millenium Development Goals. The Lancet, 
364, 900-906. 
Global Alliances 30 
United States Department Of Health And Human Services (2007). Pandemic influenza: the road 
to preparedness. Statement by Anthony S. Fauci, MD, before the Committee on 
Appropriations eta!, United States Senate. January 24, 2007 
United States Department Of Health And Human Services. (2005). The role of NIH biomedical 
research in pandemic influenza preparedness: Statement by Anthony S. Fauci, MD, 
before the Committee on Government Reform, United States House of Representatives. 
Widdus, R. (2001). Public-private partnerships for health: their main targets, their diversity, and 
their future directions. Bulletin of the World Health Organization, 79(8), 713-720. 
World Health Organization (2004). The World Health Report 2004 Retrieved February 17, 2007, 
from World Health Organization Web Site: http://www.who.int/en/ 
World Health Organization. (2006, February). Avian influenza ("bird flu")--Fact sheet. Retrieved 
February 27, 2007, from 
http://www.who.int/mediacentre/factsheets/avian_influenza!en/print.html 
Appendix 1. Network Structure and Protocol Development Process 
SEA ICRN 
Network Steering 
l j- Committee DSMB WHO, US NIAID, Wellcome Trust, Oxford University, 
Representatives of Vietnam, Thailand 
and Indonesia 
I 
Network Coordinating 
Global Alliances 31 
·---~-~~--.-· ~s: ~--- . : -~-~------:_: -~~~'-~- -Cl -----------~~Nt< 
I ADVISORY I COMMITTEES 
I Data Management 
Laboratory 
Pharmacy 
! Pharmacokinetics Center r---------------- ! Regulatory Affairs OUCRUCIRAS i Site Management 
[Trial Operationsl l Protocol Teams J ! Training Committee 
1 US NIH J H Bamrasnaradura l Ejikman Institute } National Institute fo} Infectious Disease Infectious and Clinical Center Hospital 
· Tropical Disease 1 Oxford University j H_ Chest Hospital J I National Institute for1 r-Health Research and National Pediatric J-Administrative Support Development Indonesia Hospital M Vietnam Country~ Country Coordinating Group 
Coordinating H Mahidol University } Group Children's Hospital J-l Thailand co_untry J- Faculty of Tropical l Persahabatan #1 Coordinatmg Medicine Hospital HCMC Group K Queen Sirlkit l Prof Dr Sulianti J- l Chlldren_;:2 Hospital} Children's Hospital Soeroso Hospital I HCMC ~ Sirriraj Hospital I l Hospital for Tropical} I Diseases I 
I I HCMC I lndeoendent 
•--------------------- Monitors 
~ 
~ 
z> 0~-!Cil \)2J.~C: 0 Ill -.'tl 
:u il 5·"8 )Ill~_::. 
•:~: 
s:[ 
" ~~ g,a_ 
,, 
•• 
0-1 (iO 
.,(') 
~.g 
:;C. 
.. z 
~ 
l 
lmplimentation DSMB Review 
and Results and EC 
Dissemination Approval 
liD • I 
~ 
' l 
i 
0 , 
~' ' 
' 
'> oo 
"• a<, . 
• 
Protocol 
Development 
~. 0 , 
Review 
~ 
L!'J I 
Concept 
Development 
!@, 
, 
" 
-
, 
a 
0 
n 
0 
-
c 
~ 
CD 
-0 
"C 
3 
CD 
::l 
... 
, 
0 
n 
CD 
fJI 
fJI 
I 
(/) 
m )> 
-0 
IJ 
z 
·~·.··., ' I ~· l I I l I ri 
f 
9 
0 
cr' 
e. 
2:: 
~r 
bl 
w 
(,.) 
N 
Global Alliances 33 
Appendix 2. Draft Annual Meeting Agenda 
SEA INFLUENZA CLINICAL RESEARCH NETWORK 2No ANNUAL MEETING 
16- 18 MAY, 2007 
Bangkok Marriot Resort and Spa 
Bangkok, Thailand 
PURPOSE: 
1. To provide an update on the current status of present and future Network 
research projects. 
2. To provide a technical update on Avian and pandemic influenza; 
3. To review the structure of the Network and responsibilities of the Network 
Committees and the Network Coordinating Center (NCC). 
4. To allow Network committees to meet and address specific committee 
training needs. 
LEARNING OBJECTIVES: 
At the end of this conference, the attendees will have: 
• an awareness of the current status of ongoing Network projects. 
• an increased knowledge base of AI and pandemic influenza. 
• their outstanding questions and management issues for current activities 
answered. 
• their selected new research ideas targeted for expanded proposal 
development. 
• continued consolidation and strengthening of institutional, national and 
regional teams and Networks. 
• a draft work plan for Network based protocol development and 
implementation. 
• an understanding of the launching of Network training activities. 
MEETING ROOMS: 
General Sessions will take place in the Chao Pray Ballroom. 
Concurrent Sessions and Committee Meetings will be assigned to either 
the Charoen Nakorn Room or the Thonburi Room. 
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Meeting Agenda 
TUESDAY, 15 MAY 
ARRIVAL AND CHECK IN DURING THE DAY ~---~····-~---~~-- .. ----~~----~------~~~------------·---------·--· --
'-c--1_8_.0_0_-_18_.4_5-! __ C_O_C_KT_A_IL_S_-_C_H_A_o_P_RA_Y_A_B_A_L_L_R_O_O_M _________ _j 
WELCOMING REMARKS 
• Professor Tawee Chotpitayasunondh 
• Dr. Libby Higgs 
• Dr. Jeremy Farrar 
18.45 - 19.30 KEYNOTE ADDRESS 
• Jimmy Whitworth 
19.30 - 21.00 DINNER- CHAO PRAY A BALLROOM 
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Meeting Agenda 
WEDNESDAY, 16 MAY 
BREAKFAST MEETINGS 
1. Country Lead Investigators 
Lead Investigators from Thailand, Vietnam and Indonesia meet to 
discuss country updates with Dr. Farrar, Dr. Higgs and Dr. 
7.30- 8.30 Whitworth. 
2. Meet the Experts 
Opportunity for junior investigators to meet with invited speakers I 
and well known authorities in the field of influenza and infectious 
disease research. Open to all attendees. 
WELCOME 
8.30- 8.45 Professor Jimmy Whitworth, Chair of the Network Steering 
Committee 
COUNTRY UPDATES ON INFLUENZA EPIDEMIOLOGY 
A representative from each country will present what the current 
epidemiologic status of influenza is their country and what their 
8.45- 9.30 progress is on study initiation for study SEA-001. 
I 10 minutes presentation + 5 minutes Q&A I per country. 
• Prof. Tawee Chotpitayasunondh, Thailand 
I • Prof. Nguyen Due Hien, Vietnam 
• Prof. Santoso Soeroso, Indonesia 
NETWORK STRUCTURE 
9.30- 9:50 Review of the Network structure and roles of Network committees. 
Over view of the country team concept. 
• Dr. Jeremy Farrar 
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9.50- 10.15 COFFEE BREAK 
NCC UPDATE 
Update on the role of the Network Coordinating Center(NCC) and 
10.15 - 10.45 upcoming training opportunities within the Network. Where we have 
been and where we are now. 
• Dr. Jeremy Farrar 
• Dr. Libby Higgs 
QUESTION & ANSWERS REGARDING THE NETWORK STRUCTURE 
AND NCC 
Members from the audience will have the opportunity to ask questions 
10.45 - 11:15 
about the Network structure and the NCC. Audience is welcome to 
stand and ask a question or write a question on the cards provided. 
! 
i Translators will be available for questions written in local languages. I I 
I 
• Elaine Stockwell, Moderator 
UPDATE ON SEA NETWORK STUDIES 
An update will be provided on the progress of SEA studies 001, 002 
and 003. Protocol concept for SEA studies 004 and 005 will also be 
11.15- 12.15 presented. 10 minutes presentation + 5 minutes Q&A I per 
presentation. 
• Dr. John Beigei-SEA-001 
• Dr. Nick Day-SEA-002 
• Prof. Sasithon-SEA-003 
• TBD-SEA 004 and 005 
12.15 - 13.30 I LUNCH 
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REPORT FROM THE 2ND WHO CONSULTATION ON CLINICAL 
13.30 - 14.00 
ASPECTS OF HUMAN INFECTIONS WITH H5N1 VIRUS I 
I 
A review of the highlights and recommendations from the report. 
• Dr. Menno de Jong 
INTENSIVE TREATMENT UNIT MANAGEMENT 
A description of genetic susceptibility to pneumonia and Acute 
Respiratory Distress Syndrome (ARDS). A review of the data 
14.00 - 14.45 demonstrating reduced mortality with lung protective ventilation and 
increased mortality with steroids in (ARDS)/sepsis. An evaluation of 
I 
Sequential Organ Failure Assessment (SOFA) score for prediction of 
mortality in intensive care unit (ICU) patients. 
• Dr. Jean Daniel 
I 14.45 - 15.15 COFFEE BREAK 
AI CASE MANAGEMENT 
A clinical case study presentation of a recent case of Avian Influenza, 
15.15 - 16.00 including patient assessment, clinical course, treatment and lab 
values. 
• Dr. Tjandra Yoga Aditama 
• Dr. Sorasak - Pediatric Management 
·. ·· .. ·.· 
. 
•• 
16.00- 17.00 r COMMITTEE MEETINGS. AND COMMITTEE SPECIFIC TRAINING: 
SITE MANAGEMENT 
Thonburi 
Committee chairs and lead CTSS to discuss purpose and role of the 
Room 
committee in the Network; review leadership structure, and review 
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SMC training with study coordinators and site CTSS for the following 
day. 
• Christian Yoder 
• Elaine Blackwell 
• Pongphaya Choosakulchart 
• Sujitra Sundarasardula 
• Peggy Coyle 
• Hasan Basri 
CLINICAL 
Case study presentation and hands-on exercises for potential 
Charoen 
AE/SAE for SEA-001 study. Review of Toxicity table. 
Nakorn Room • Joseph Chiu and Bob Taylor, Moderators 
• All study Investigators 
• Study sub-Investigators 
• Study Coordinators 
PHARMACY 
'14 of Chao Discuss lessons learned implementing the study drug shipping and 
Praya pharmacy specific procedures, and how we can enhance the 
Ballroom procedures for the Oseltamivir Study and for future studies. 
• Antonia Kwiecien and Watcharee Lemankul, Moderators 
• All study Pharmacists 
• 
DATA MANAGEMENT 
1f4 of Chao 
Pray a 
To discuss current and future status of data management for the Network. 
• Patrick Murphy and Barbara Avery, Moderators 
Ballroom • All members of the RDMC 
• All Data Managers 
114 of Chao 
Praya 
Ballroom 
1f4 of Chao 
Praya 
Ballroom 
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REGULATORY 
To discuss role of the regulatory committee in the Network. 
• John Tierney, Moderator 
• All members of the Regulatory Committee 
-~--------~~- ·--~·---·----~~··--·-·-----~----···----·-·-·-·-- .. -·--~~------------ : 
lAB 
To discuss current and future status of the laboratory committee for the 
Network. 
• 
• 
Menno de Jong and Heiman Wertheim, Moderators 
All study lab staff 
Global Alliances 40 
Meeting Agenda 
THURSDAY, 17 MAY 
07.30 - 08.30 
08.30- 09.30 
9.30- 10.15 
10.15- 10.30 
OPTIONAL BREAKFAST MEETING - MEET THE EXPERTS 
Opportunity for junior investigators to meet with invited speakers and 
well known authorities in the field of influenza and infectious disease 
research. Open to all attendees. 
ANIMAL MODELS AND PRECLINICAL TESTING OF NOVEL 
THERAPEUTIC AGENT 
Overview of novel mathematical method to study variation of influenza 
virus strains as they emerge. In addition, a reverse genetics system 
and new molecular systems have been established, which will be useful 
for the rapid production of influenza vaccines. 
45 minutes presentation + 15 minutes Q&A. 
• Prof. Albert Osterhaus, Professor of Virology, Medical Faculty, 
Erasmus MC, Rotterdam 
OVERVIEW OF DSMB 
Presentation of the role and purpose of a Data Safety Monitoring Board 
(DSMB). Discussion of why DSMBs are desired and how they operate. 
Introduction of the Network DSMB, the members and their 
responsibilities. 30 minutes presentation + 15 minutes Q&A. 
• Dr. Mario Chen 
BREAK 
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CONCURRENT SESSION A i CONCURRENT SESSION B 
10.30 - 11.30 
. CHAO PRAY BALLROOM CHAROEN NAKORN ROOM 
AE/SAE REPORTING AND LABORATORY QUALITY AND 
EMERGENCY UN BLINDING ISO 15189 CERTIFICATION 
To provide a clear understanding A short review on criteria of 
of the roles and responsibilities clinical laboratory assurance 
surrounding AE/SAE reporting ISO 15189 
• Janet Robinson 
within the Network. 
• Kelly Cahill 
• Cynthia Kleppinger 
• Dr. Bob Taylor 
CONCURRENT SESSION A CONCURRENT SESSION B 
11.30- 12.15 
i CHAO PRAY BALLROOM CHAROEN NAKORN ROOM 
INFORMED CONSENT PANEL ASSAYING ANTI-INFLUENZA 
A panel discussion on the cultural DRUGS 
challenges and solutions for meeting Overview of susceptibilities of 
the requirements of infomed consent influenza viruses and their 
when consenting minors into clinical drug-resistant variants to 
studies. 
• Susan Vogel neuraminidase inhibitors in the 
• Peggy Coyle 
• Pongphaya Choosakulchart NA inhibition assay. 
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I Hasan Basri I • • Niklas Lindegard I 
I I 
CLINICAL MONITORING EXPECTATIONS 
Brief overview what will be included in a monitoring visit. What 
monitors will ask and what they will review. What will be included in 
12.15 - 12.30 
I 
the monitoring reports? How to prepare for a monitoring visit, 
maintenance of regulatory binder and essential documents. 
Responsibilities of clinical staff during a monitoring visit. 
• Susan Vogel 
I 
12.30 - 13.30 LUNCH I 
VIRAL DRUG RESISTANCE 
Oseltamivir resistance can have much graver consequences in H5N1 
cases than in ordinary flu. In the latter, drug resistance has not been 
13.30 - 14.00 associated with treatment failure or a severe outcome, but "with H5N1 
this may be a very different outcome." A review of sequence analysis of 
the H5N1 virus's neuraminidase gene to look for resistance, signaled by 
the substitution of tyrosine for histidine at amino acid position 274. 
• Dr. Menno de Jong 
PRACTICAL LESSONS TO BE LEARNED FROM MATHEMATICAL MODELS 
OF INFLUENZA 
14.00 - 15.00 
How mathematical models are used to predict the likelihood of 
emeraina novel human influenza virus subtypes and help prepare for 
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possible pandemics. How mathematical models are used to derive 
estimates for the levels of drug stockpiles needed to buy time, how and 
when to modify vaccines, whom to target with vaccines and drugs, and 
when to enforce quarantine measures. 45 minutes presentation + 15 
minutes Q&A. 
• Prof. Derek J. Smith 
15.00 - 15.30 BREAK 
15.30- 17.00 COMMITTEE MEETINGS/REPORTS AND COMMITTEE SPECIFIC 
TRAINING: 
Thonburi Room SITE MANAGEMENT 
Present the role and purpose of the SMC to all the study Coordinators. 
Discuss the role and responsibilities of the study coordinator in Network 
studies. Review of data discrepancy forms. 
• All Study Coordinators 
• All CTSS 
Charoen Nakorn CLINICAL 
Room 
WHAT IS THE 1572 AND HOW DOES IT AFFECT YOU? 
An overview of the 1572 forms and PI responsibilities as stated in the 
document. Relationships and obligations Pis have to the IRB. 
Common mistakes made during clinical trials. 
AUDITS AND FDA WARNINGS? 
What is an audit? What is an FDA warning? What to do if you get 
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audited. 
• Joseph Chiu and Bob Taylor, Moderators 
• Julie Welch, presenter 
• Kelly Cahill, presenter 
• All study Investigators 
• Study sub-Investigators 
'14 of Chao Praya PHARMACY 
Ballroom 
Review pharmacy forms completion. 
• Antonia Kwiecien and Watcharee Lemankul, Moderators 
• All study Pharmacists 
1f4 of Chao Praya DATA MANAGEMENT 
Ballroom Continue discussion on current and future status of data management for the 
Network. 
• Patrick Murphy and Barbara Avery, Moderators 
• All members of the RDMC 
• All Data Managers 
1f4 of Chao Praya REGULATORY 
Ballroom 
Continue discussion on role of the regulatory committee in the Network. 
• John Tierney, Moderator 
• All members of the Regulatory Committee 
1f4 of Chao Praya LAB 
Ballroom 
Continue discussion on current and future status of the laboratory committee for 
the Network. 
• Menno de Jong and Heiman Wertheim, Moderators 
• All study lab staff 
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Meeting Agenda 
fRIDAY, 18 MAY 
07.30 - 08.30 
08.30 - 09.00 
09.00 - 09.30 
09.30 - 10.00 
OPTIONAL BREAKFAST MEETING - MEET THE EXPERTS 
Opportunity for junior investigators to meet with invited speakers 
and well known authorities in the field of influenza and infectious 
disease research. Open to all attendees. 
PROTOCOL TEAM OVERVIEW 
Presentation of who should be on a protocol team. What are the 
responsibilities of a protocol team: protocol design 
implementation, amendments, reports, publications, and 
responsibilities to the DSMB. 
• Dr. Joseph Chiu 
J PROTOCOL DEVELOPMENT PROCESS IN THE NETWORK 
Considerations for protocol development; what needs to be 
included from the perspective of Code of Federal Regulations and 
ICH guidelines. Steps from inception to publishing. 
• Dr. Bob Taylor 
IND REGULATIONS 
What is an IND study? Broad overview of process from concept 
development, validation, preclinical testing, IND application 
process, Phase I-III studies, up to NDA application. 
• John Tierney 
10.00- 10.15 
10.15- 11.15 
11.15 - 11.45 
11.45- 12.15 
12.15 - 12.30 
12.30 - 13.30 
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COFFEE BREAK 
CLINICAL TRIAL DESIGN - WHAT TO CONSIDER WHEN 
DESIGNING A STUDY 
Review of reasoning behind randomization; analytical hazards 
imposed by not doing a randomized clinical trial. A discussion 
about the ethics of clinical research requirement of equipoise as a 
state of genuine uncertainty on the part of the clinical investigator 
regarding the comparative therapeutic merits of each arm in a 
trial. 
• Kevin Baird 
• Libby Higgs 
PRESENTATION OF INVESTIGATOR'S CONCEPTS FOR RESEARCH 
Investigators will present ideas for future research. 
• Dr. Joseph Chiu, Moderator 
FUTURE OF THE NETWORK 
Panel discussion and Q & A of the vision for the Network. Save the 
date for nest year's meeting in Indonesia. 
• Dr. Jeremy Farrar 
• Dr. Tawee Chotpitayasunondh 
• Dr. Sangkot Marzuki 
• Prof. Nguyen Due Hien 
WRAP Up AND CLOSING 
• Dr. Jeremy Farrar 
• Dr. Tawee Chotpitayasunondh 
• Dr. Libby Higgs 
LUNCH -ADJOURN 
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